ReviewBMC medicine2013
Genetic heterogeneity in breast cancer: the road to personalized medicine?
Review in BMC medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer.Cancer research · 2024Article
- Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple-Negative Breast Cancer Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases.Science advances · 2022Article
- Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.Breast cancer research : BCR · 2021Article
- Genome-Wide Estrogen Receptor Activity in Breast Cancer.Endocrinology · 2021Review
- CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents.Frontiers in oncology · 2021Review
- Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells.Cells · 2020Article
- Starvation stress attenuates the miRNA-target interaction in suppressing breast cancer cell proliferation.BMC cancer · 2020Article
- Integrative Analysis of Breast Cancer Cells Reveals an Epithelial-Mesenchymal Transition Role in Adaptation to Acidic Microenvironment.Frontiers in oncology · 2020Article
- Targeting acidity in cancer and diabetes.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Gene editing in the context of an increasingly complex genome.BMC genomics · 2018Review
- Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data.Journal of bone oncology · 2018Review
- Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer.Oncology letters · 2017Article
- Phenotypic changes of acid-adapted cancer cells push them toward aggressiveness in their evolution in the tumor microenvironment.Cell cycle (Georgetown, Tex.) · 2017Article
- The zinc-finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer.Oncogenesis · 2017Article
- A murine preclinical syngeneic transplantation model for breast cancer precision medicine.Science advances · 2017Article
- The Cellular Origin and Evolution of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- How the effects of aging and stresses of life are integrated in mortality rates: insights for genetic studies of human health and longevity.Biogerontology · 2016Review
- MutAid: Sanger and NGS Based Integrated Pipeline for Mutation Identification, Validation and Annotation in Human Molecular Genetics.PloS one · 2016Article
- A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
More women die from breast cancer across the world today than from any other type of malignancy. The clinical course of breast cancer varies tremendously between patients. While some of this variability is explained by traditional clinico-pathological factors (including patient age, tumor stage, histological grade and estrogen receptor status), molecular profiling studies have defined breast cancer subtypes with distinct clinical outcomes. This mini-review considers recent studies which have used genomics technologies in an attempt to identify new biomarkers of prognosis and treatment response. These studies highlight the genetic heterogeneity that exists within breast cancers in space and time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.